125735-34-4

Upstream product

• 103440-52-4 methyl 2-iodo-5-methylbenzoate 
• 463976-21-8 α,α,α-trifluoro-o-iodo-p-cresol 
• 99-04-7 m-Toluic acid 
• 2941-78-8 2-Amino-5-methylbenzoic acid 

Downstream Products

• 1187237-91-7 C₈H₆BrIO₂ 
• 1187238-27-2 C₈H₇IO₃ 
• 1378430-69-3 methyl 5-((N-(5-cyclopropyl-2-(3-fluorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-iodobenzoate 
• 1378430-79-5 methyl 5-((N-(5-cyclopropyl-3-(methylcarbamoyl)-2-(4-(trifluoromethyl)phenyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-iodobenzoate 
• 1378430-73-9 methyl 5-((N-(5-cyclopropyl-2-(4-chlorophenyl)-3-(methylcarbamoyl)benzofuran-6-yl)methylsulfonamido)methyl)-2-iodobenzoate 
• 1378430-90-0 methyl 5-((N-((5-cyclopropyl-2-(4-(4-fluorophenoxy)phenyl)-3-(methylcarbamoyl)benzofuran-6-yl))methylsulfonamido)methyl)-2-iodobenzoate 
• 1349029-04-4 C₃₄H₄₁F₃N₈O₇ 
• 1349029-02-2 C₄₉H₅₃F₃N₈O₉ 
• 1349029-01-1 C₃₂H₃₇N₃O₇ 
• 1349028-98-3 C₃₃H₃₉N₃O₇ 
• 1349028-95-0 C₂₁H₂₃NO₆ 
• 1349028-94-9 C₂₀H₂₂INO₄ 
• 1349028-92-7 C₁₂H₁₆INO₂ 

Relevant academic research and scientific papers

BORON-CONTAINING PHARMACOPHORE

Provided herein are boron-containing compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders.

QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS

The present invention relates to compounds of formula (I) and compositions containing said compounds acting as PARP (Poly (ADP- ribose) polymerase) inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS

Methods are provided for modulating MRGPR X4 generally, or for treating a MRGPR X4 dependent condition more specifically, by contacting the MRGPR X4 or administering to a subject in need thereof, respectively, an effective amount of a compound having the structure of Formula (I): (I) or a pharmaceutically acceptable isomer, racemate, hydrate, solvate, isotope, or salt thereof, wherein n, x, A, Q1, Q2, Z, R, R1, R2, R3, R4 and R5 are as defined herein. Pharmaceutical compositions containing such compounds, as well as to compounds themselves, are also provided.

PYRROLE COMPOUNDS, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Compounds of formula (I): wherein A1, A2, Ra, Rb, Rc, Rd, R3, R4, R5 and T are as defined in the description. Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

COMPOUND, SYNTHESIS, COMPOSITION AND USES THEREOF

The instant application provides the disclosure for a compound of formula I, synthesis of compound of formula I and its pharmaceutical acceptable salts, as well as its polymorphs, solvates, and hydrates thereof. The pharmaceutically acceptable salt may be

Design, synthesis and identification of novel colchicine-derived immunosuppressant

Synthesis and biological evaluation of various colchicine analogues through the mixed-lymphocyte reaction (MLR), lymphoproliferation, and inhibitory effects on the inflammatory genes are described. In addition, a new series of immunosuppressive agents developed on the structural basis of colchicine, as well as their structure-activity relationships is reported. The most potent analogue 20a exhibited an excellent immunosuppressive activity on in vivo skin-allograft model, which is comparable to that of cyclosporin A.

Immobilized Iodosobenzoate Catalysts for the Cleavage of Reactive Phosphates

Titanium dioxide and nylon covalently supported iodosobenzoate reagents 11 and 19 have been prepared by the procedures outlined in Schemes I and II.Both 11 and 19 are good catalysts for the cleavage of p-nitrophenyl diphenyl phosphate (PNPDPP) under heter